-

FDA grants IPS HEART Orphan Drug Designation for GIVI-MPC for Treatment of Duchenne Muscular Dystrophy

HOUSTON--(BUSINESS WIRE)--IPS HEART has been granted orphan drug designation by the FDA for GIVI-MPC, a first-in-class stem cell therapeutic to create new skeletal muscle with 100% full length dystrophin for the treatment of patients with Duchenne Muscular Dystrophy(DMD).

The FDA has granted an orphan drug designation (ODD) to GIVI-MPC, a first-in-class IPS stem cell therapeutic for the treatment of patients with Duchenne Muscular Dystrophy. Current treatments for DMD have limited therapeutic potential as unfortunately none can create any new skeletal muscle or can deliver 100% full length human dystrophin. GIVI-MPC has succeeded in creating new human skeletal muscle with 100% full length human dystrophin in both mdx mice and dystrophic pigs. While there is a lot of hope with newer DMD gene therapy approaches, unfortunately to date there has been no reversal of the underlying disease as gene therapy can only deliver a fraction of the dystrophin gene (~30%) and cannot create any new skeletal muscle.

IPS HEART, founded in 2014, around cardiac and rare muscle diseases is on track to be the first IPS stem cell company to advance its first in class disease modifying therapy into human clinical trials. “Given our successful pre-IND meeting with the FDA and our ongoing developmental efforts including GMP manufacturing, we believe that we will be the first IPS stem cell company with a disease modifying therapy to advance both drugs into human clinical trials whereby all current drugs largely only provide symptomatic relief,” said Rauf Ashraf, CEO of IPS HEART. While heart attacks still kill more annually then all forms of cancer combined, IPS HEART’s first drug candidate ISX9-CPC has created significant new heart regeneration with new functional human heart muscle 90 days after heart attack with its patented human IPS stem cell platform.

About the FDA Orphan Drug Designation

Orphan Drug Designation provides various development benefits for an investigational drug, including seven-year exclusivity after marketing approval is received.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a rare, fatal neuromuscular genetic disease with patients usually succumbing to the disease in their twenties.

About IPS HEART/GIVI-MPC

GIVI-MPC is IPS HEART’s second drug candidate that uses the small molecule Givinostat to reprogram human iPSCs into new skeletal muscle tissue while also delivering 100% full-length human dystrophin for the treatment of Duchenne Muscular Dystrophy.

IPS HEART


Release Summary
FDA grants IPS HEART Orphan Drug Designation for GIVI-MPC for Treatment of Duchenne Muscular Dystrophy
Release Versions

More News From IPS HEART

FDA Grants Orphan Drug Designation to IPS HEART’s GIVI-MPC Stem Cell Therapy for Becker Muscular Dystrophy

HOUSTON--(BUSINESS WIRE)--IPS HEART has been awarded Orphan Drug Designation (ODD) by the FDA for GIVI-MPCs based on its unique ability to create new muscle with full length dystrophin in Becker Muscular Dystrophy(BMD). IPS HEART has now shown GIVI-MPCs create new human muscle with full length human dystrophin in dystrophic pigs, young and extremely aged Duchenne Muscular Dystrophy (DMD) mice and in a sarcopenia mouse model. The FDA previously awarded GIVI-MPCs Orphan Drug Designation for DMD,...

IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapy’s Ability to Create New Skeletal Muscle in Aged Mice

HOUSTON--(BUSINESS WIRE)--IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop new skeletal muscle and cardiac muscle generation treatments for Duchenne Muscular Dystrophy (a rare disease) and heart failure, today announced the peer-reviewed publication of in vivo and in vitro study with its GIVI-MPC stem cell therapy candidate in this month's issue of Cells (volume 12, issue 14). The study, “Chemokine/ITGA4 Interaction Directs iPSC-Derived Myogenic Proge...

IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease

HOUSTON--(BUSINESS WIRE)--IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop new skeletal muscle and cardiac muscle generation treatments for Duchenne muscular dystrophy (a rare disease) and heart failure, today announced that the U.S. Food and Drug Administration (FDA) awarded a third Rare Pediatric Drug Designation (RPDD) for its product candidate, ISX9-CPC, for treatment of cardiomyopathy associated with Danon disease. ISX9-CPC stem cell therapeutic...
Back to Newsroom